Spectral CT image showing a pulmonary embolism (PE).
New late-breaking data presented at ESC Congress 2026 adds to the growing evidence that more invasive catheter-based pulmonary embolism procedures can improve patient outcomes.
While T-TEER is already known to improve a patient's quality of life, this late-breaking study from ESC Congress 2026 confirmed it also improves survival and reduces the risk of heart failure hospitalization.
Caristo's FAI imaging AI is FDA-cleared for the detection of inflammation in coronary arteries, but research is also looking at its use in detecting the cause of AFib and heart failure. Image courtesy of the European Heart Journal.
AI technology developed by Caristo Diagnostics was the focus of multiple studies presented at ESC Congress 2026.
It was a relatively small study, and patients were only followed for six months, but these late-breaking data out of ESC Congress 2026 give care teams a lot to consider.
Many patients who need TAVR also present with coronary artery disease. According to new data presented at ESC Congress 2026, performing TAVR first is noninferior to performing PCI first.
New data presented at ESC Congress 2026 represent a huge breakthrough for patients with nonobstructive HCM. "For the first time, we have shown clinically meaningful improvements in symptoms and exercise capacity with a treatment that targets the cause of the disease," one researcher explained.
Imager II Angiographic Catheters. Image courtesy of Boston Scientific.
The issue, brought on by a manufacturing defect, has been linked to two serious injuries. The FDA shared an early alert about the situation as it continues its investigation.
